Welcome to our dedicated page for Axt news (Ticker: AXTI), a resource for investors and traders seeking the latest updates and insights on Axt stock.
AXT, Inc. (AXTI) is a material science company that develops and manufactures high-performance compound and single element semiconductor substrate wafers, with a focus on indium phosphide, gallium arsenide and germanium. The company’s news flow reflects its role in supplying specialty substrates for applications such as 5G infrastructure, data center connectivity using silicon photonics, passive optical networks, LED lighting, lasers, sensors, power amplifiers for wireless devices and satellite solar cells.
News about AXT often centers on quarterly financial results, where the company reports revenue, margins and net income or loss, along with management commentary on demand trends for its substrates. Investors can follow updates on how export control permits in China affect shipments of indium phosphide and gallium arsenide products and how these factors influence reported revenue in specific periods.
AXT also issues press releases about capital markets activity, including underwritten public offerings of common stock under its shelf registration statement on Form S-3. These announcements describe intended uses of proceeds, such as expanding manufacturing capacity at its subsidiary Beijing Tongmei Xtal Technology Co., Ltd., supporting research and development of new or improved products and funding general corporate and working capital needs.
Additional AXTI news items include participation in investor conferences, preliminary revenue ranges ahead of earnings releases, updates on the proposed STAR Market listing of its Tongmei subsidiary, and corporate governance developments such as board changes and Nasdaq listing rule compliance matters. For investors tracking AXTI stock, this news page provides a centralized view of company press releases and related disclosures that describe operational performance, regulatory developments and strategic priorities.
AXT (NasdaqGS: AXTI) announced that underwriters exercised the full over-allotment option in its recent public offering, purchasing an additional 1,284,046 shares at $64.25 per share for approximately $82.5 million in additional gross proceeds. The original offering comprised 8,560,311 shares, bringing total shares sold to 9,844,357.
According to the company, net proceeds will primarily support its Beijing subsidiary's capacity expansion for indium phosphide substrate production for export, fund research and development, and provide working capital and general corporate purposes. The shelf registration was filed April 20, 2026.
Tradr ETFs will launch four single-stock 2X leveraged ETFs on Cboe on April 24, 2026, each seeking 200% of the daily performance of its underlying stock.
Expected launches include AXTX (AXTI), CPNX (CPNG), MPWX (MPWR) and STXX (STX). The issuer highlighted significant risks of leveraged ETFs and directs investors to its website for full disclosures.
AXT (NasdaqGS: AXTI) closed an underwritten public offering of 8,560,311 common shares at $64.25 per share, generating approximately $550 million in gross proceeds.
The underwriter has a 30-day Overallotment Option for an additional 1,284,046 shares, which if exercised would raise aggregate gross proceeds to about $632.5 million. The company intends to use net proceeds to support its Beijing subsidiary’s indium phosphide capacity expansion, fund R&D, and for working capital and general corporate purposes.
AXT (NasdaqGS: AXTI) priced an underwritten public offering of 8,560,311 shares at $64.25 per share, expected to raise approximately $550 million in gross proceeds before fees. The underwriter has a 30-day Overallotment Option for 1,284,046 additional shares, potentially increasing gross proceeds to $632.5 million.
Closing is expected on or about April 22, 2026, subject to customary conditions. Net proceeds are intended to support subsidiary Beijing Tongmei Xtal Technology's capacity expansion for indium phosphide substrate exports, R&D, working capital, and general corporate purposes.
AXT (NasdaqGS: AXTI) announced an intended public offering of common stock on April 20, 2026, with an underwriter Overallotment Option of up to 15% of the shares. Net proceeds are planned to support subsidiary Beijing Tongmei Xtal Technology’s capacity expansion, R&D, working capital and general corporate purposes.
The offering is subject to market conditions; final terms will be disclosed in a prospectus supplement filed with the SEC.
AXT (NasdaqGS: AXTI) will release first quarter 2026 financial results after market close on April 30, 2026 and hold a conference call the same day at 1:30 p.m. PT.
Investors can join by phone (833-461-5787, passcode 619252830) or via live webcast at www.axt.com. The webcast will remain available through April 30, 2027.
AXT (NasdaqGS: AXTI) reported fourth quarter and fiscal year 2025 results, with Q4 revenue $23.0M and fiscal 2025 revenue $88.3M. GAAP gross margin fell to 12.7% for fiscal 2025 and GAAP net loss widened to $21.3M ($0.49/share). Management said permit receipts improved in early 2026 and the company expects sequential revenue growth in Q1 as it doubles indium phosphide capacity.
The company will host a conference call today at 1:30 p.m. PT and noted the STAR Market IPO process for its Tongmei subsidiary remains under regulatory review.
AXT (Nasdaq: AXTI) updated its Q4 2025 revenue outlook to $22.5–$23.5 million, citing fewer export permits for indium phosphide issued by China’s Ministry of Commerce that limited December shipments. The company said customer demand remains strong and expects additional permits in Q1 2026. AXT completed a capital raise in December and plans to use proceeds to expand manufacturing capacity, targeting more than double indium phosphide capacity in the second half of 2026 to support AI and optical connectivity demand.
AXT will release Q4 2025 results and host an earnings call on Feb 19, 2026 at 1:30 p.m. PT; replay available through Feb 26, 2026.
AXT (Nasdaq: AXTI) closed an underwritten public offering of 8,163,265 shares of common stock at $12.25 per share on December 30, 2025, including full exercise of the underwriters’ option to purchase an additional 1,064,773 shares.
The company received approximately $100 million gross proceeds before underwriting discounts, and intends to use net proceeds primarily to increase manufacturing capacity at its Beijing Tongmei Xtal subsidiary to produce indium phosphide substrates for export, for research and development, and for general corporate and working capital purposes.
Northland Capital Markets acted as sole bookrunner; Wedbush and Craig-Hallum served as co-managers. The offering was made under an S-3 shelf registration effective November 27, 2025.
AXT (Nasdaq: AXTI) priced an underwritten public offering of 7,098,492 shares at $12.25 per share, generating gross proceeds of approximately $87.0 million. The company granted a 30‑day overallotment option for up to 1,064,773 additional shares, which if fully exercised would raise aggregate gross proceeds to about $100 million. The offering is expected to close on or about December 30, 2025, subject to customary conditions. Net proceeds are intended primarily to expand manufacturing capacity at Beijing Tongmei Xtal to produce indium phosphide substrates for export, and for R&D and general corporate and working capital purposes. Northland Capital Markets is sole bookrunner; Wedbush and Craig‑Hallum are co‑managers.